Physician profile
Eileen Anne Egan
NPI 1225290364
$8,449.32
in general payments reported to CMS, 2019-2025
31 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,785 · 2022: $692 · 2023: $2,456 · 2024: $1,332 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285 · Consulting Fee: $1,590 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.79 |
| Consulting Fee | $1,590.00 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,914.22 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $417.19 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $198.80 | 2022-2024 | |
| Averitas Pharma INC. | $189.14 | 2024 | Qutenza |
| Abbott Laboratories | $169.71 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $139.16 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $129.73 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $112.34 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $110.93 | 2023-2024 | |
| Lilly USA, LLC | $109.80 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $107.23 | 2021-2024 | Lokelma |
| Tandem Diabetes Care, INC. | $95.14 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $94.20 | 2021-2023 | Omnipod |
| Corcept Therapeutics | $91.06 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $77.73 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $75.31 | 2022-2024 | Injectafer |
| Rhythm Pharmaceuticals, INC. | $53.11 | 2023 | Imcivree |
| Ibsa Pharma INC. | $43.48 | 2022 | |
| Cequr Corporation | $38.54 | 2022-2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.87 | 2022 | |
| Spinal Simplicity, LLC | $37.85 | 2024-2025 | Ha Minuteman G3-R |
| Merck Sharp & Dohme LLC | $32.78 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Alkermes, INC. | $24.11 | 2024 | Vivitrol |
| Ultragenyx Pharmaceutical INC. | $24.06 | 2022 | |
| Horizon Therapeutics Plc | $21.61 | 2023 | Tepezza |
| Amarin Pharma, INC. | $21.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2022 | |
| Radius Health, INC. | $16.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.33 | 2022 | |
| Nevro Corp. | $16.01 | 2024 | Senza |
| Mannkind Corporation | $14.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.